On the other hand, the effect of prasugrel is less influenced by the CYP2C19 polymorphisms, and even low-dose prasugrel reportedly achieves stronger platelet inhibition than clopidogrel in CAD patients [27–29]. This evidence concerns the gene CYP2C19 and coronary artery disorder.